Zentalis Pharmaceuticals, LLC Gains 31.29%

Zentalis Pharmaceuticals, LLC (ZNTL:NASDAQ) shot up at $2.14, representing a gain of 31.3%. The stock got featured on our News Catalysts scanner on Mon, Feb 03, 2025 at 07:07 PM in the 'PRIVATE PLACEMENT' category. From Wed, Jan 22, 2025, the stock recorded 40.00% Up Days and 54.55% Green Days

The stock spiked on Mon, Sep 16, 2024 at $5.44 with a volume of 44M+.

About Zentalis Pharmaceuticals, LLC (ZNTL:NASDAQ)

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.